Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 76

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 76
---
 requires us to
be successful in a number of challenging, uncertain and risky activities, including pursuing development of our gene therapy product candidates
in indications for which we have limited or no human clinical data, designing and executing a nonclinical and/or clinical development
program for our product candidates, building internal or outsourced gene therapy capabilities, converting early stage gene therapy research
efforts into clinical development opportunities, identifying additional promising new assets for development that are available for acquisition
or in-license and that fit our strategic focus and identifying potential partners to collaborate on our products. We may not be successful
at one or more of the activities required for us to execute this business plan. In addition, we may consider other strategic alternatives,
such as mergers, acquisitions, divestitures, joint ventures, partnerships and collaborations. We cannot be sure when or if any type of
transaction will result. Even if we pursue a transaction, such transaction may not be consistent with our stockholders’ expectations
or may not ultimately be favorable for our stockholders, either in the shorter or longer term.

<div align='center'>48</div>

Our growth prospects and the future
value of our Company are primarily dependent on the progress of our ongoing and planned development programs for our product candidates
as well as the outcome of our ongoing business development efforts and pipeline progression, together with the amount of our remaining
available cash. The development of our product candidates and the outcome of our ongoing business development efforts and pipeline are
highly uncertain. We expect to continue to reassess and make changes to our existing development programs and pipeline strategy. Our plans
for our development programs may be affected by the results of competitors’ clinical trials of product candidates addressing our
current target indications, and our business development efforts and pipeline progression may also be affected by the results of competitors’
ongoing research and development efforts. We may modify, expand or terminate some or all our development programs, clinical trials or
collaborative research programs at any time as a result of new competitive information or as the result of changes to our product pipeline
or business development strategy.

If serious adverse events or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay our clinical development and commercialization of some or all of our product candidates.

Undesirable side effects or safety
concerns caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt our clinical trials and
could result in a more restrictive label or the delay or denial of regulatory